- NYSE American accepted Serina Therapeutics’ plan to regain compliance with continued listing standards.
- Cure period runs through July 9, 2027, with shares remaining listed during that time subject to other standards.
- Company received a noncompliance notice on Jan. 9, 2026 tied to stockholders’ equity of $1.6 million.
- NYSE American will monitor progress quarterly, with suspension and delisting procedures possible if targets are not met by deadline.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604021613PRIMZONEFULLFEED9683733) on April 02, 2026, and is solely responsible for the information contained therein.
Comments